SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) — Kineta, Inc. KA, a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today the presentation of new preclinical data on the company’s anti-CD27 agonist monoclonal antibodies (mAbs) in development for the treatment of…Read More
Kineta Presents New Preclinical Data on Lead AntiCD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy Kineta NASDAQKA
